Trial Search Results
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Mantle Cell Lymphoma is a sub-type of Non-Hodgkin's Lymphoma which is generally considered incurable with current therapy. Our goal is to accrue 59 patients who receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. Our hope is that vaccination will prolong the time which patients will stay in remission from their disease.
Stanford is currently not accepting patients for this trial.
Collaborator: National Institutes of Health (NIH)
- Biological: CpG-MCL vaccine, primed T-cells
- Procedure: Autologous peripheral blood stem cell transplantation
- Procedure: CT scan
- Procedure: PET-CT scan
- Drug: PF-3512676
- Drug: Rituximab
Inclusion Criteria (at time of enrollment):
- Patients must be newly diagnosed with mantle cell lymphoma, have an accessible disease
site for excisional biopsy or have sufficient peripheral blood tumor to leukapherese
at least 1.5 x 109 lymphoma cells in a single session.
- By standard clinical criteria, be medically appropriate to receive rituximab and
standard induction chemotherapy and high-dose chemotherapy with AHCT.
- Patients must be HIV negative.
- ECOG performance status 0, 1, or 2 or Karnofsky performance scale 50-100%.
- Patients must be capable of signing an informed consent.
- Patients who are currently taking immunosuppressive medications.
- Patients with severe psychological or medical illness.
- Pregnant or lactating women.
- At the discretion of the principal investigator if he/she feels that the patient is
unable to safely complete the study. Specifically, patients must be considered
medically eligible to undergo standard high dose chemotherapy and autologous stem cell
Ages Eligible for Study
21 Years - 70 Years
Genders Eligible for Study